Steatohepatitis/Metabolic Liver Disease News

VIENNA — In this exclusive video from the International Liver Congress 2019, Dean Hum, PhD, chief scientific officer and chief operating officer of Genfit, discusses the company’s therapeutic and diagnostic pipeline as well as efforts toward disease awareness.

VIENNA — In this exclusive video from the International Liver Congress 2019, Sujal Shah, MS, MBA, president and CEO of CymaBay Therapeutics, discusses the results of a phase 2 study presented at the meeting as well as other studies currently in the midst of enrolling patients.

VIENNA — In this exclusive video from the 2019 International Liver Congress, Rob Myers, MD, vice president of the liver diseases therapeutic area at Gilead, discusses a collaboration between Gilead and Novo Nordisk.

Gilead Sciences announced that the STELLAR-3 phase 3 study of selonsertib for patients with bridging fibrosis due to nonalcoholic steatohepatitis did not meet the prespecified 48-week primary endpoint of 1-stage or more histological improvement in fibrosis without worsening of nonalcoholic steatohepatitis, according to a press release.

VIENNA — Patients with nonalcoholic fatty liver disease who underwent a 12-week aerobic exercise intervention showed significant improvements in hepatic and extrahepatic parameters after review of paired biopsies, according to a study presented at the International Liver Congress 2019.

VIENNA — In this exclusive video from the International Liver Congress 2019, Matt Kelly, PhD, head of innovation and clinical science at Perspectum Diagnostics, discusses the company’s recent data on LiverMultiScan and other product information presented at the meeting.

VIENNA — Interim results from a phase 2b study of MSDC-0602K for nonalcoholic steatohepatitis demonstrated significant positive effects on liver enzymes and glycemic control, according to data presented at the International Liver Congress 2019.

VIENNA — A single dose of NGM313 demonstrated improvements in multiple noninvasive markers of nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress 2019.

VIENNA — In this exclusive video from the International Liver Congress 2019, Bajaj S. Jasmohan, MD, from the Virginia Commonwealth University and the McGuire VA Medical Center, discusses results from a study in which plasma metabolomics showed systemic differences in circulating lipid metabolites in people who followed a Middle Eastern diet vs. a standard Western Diet.

VIENNA — In this exclusive video from the International Liver Congress 2019, Gideon M. Hirschfield, MD, from the Toronto Center for Liver Disease and the University of Toronto in Canada, discusses the long-term effects of Ocaliva in patients with primary biliary cholangitis on immune and inflammatory markers.